In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经，多发性硬化以及正常人的清进行NMO-IgG测定，判断NMO-IgG是否能作视神经，多发性硬化的一项实验室依据。